Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 852,179
  • Shares Outstanding, K 66,894
  • Annual Sales, $ 38,040 K
  • Annual Income, $ -131,170 K
  • 36-Month Beta 0.13
  • Price/Sales 9.61
  • Price/Cash Flow N/A
  • Price/Book 5.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +203,977.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.99 +18.74%
on 01/29/19
13.15 -0.76%
on 02/22/19
+1.46 (+12.60%)
since 01/22/19
3-Month
10.68 +22.19%
on 12/21/18
13.79 -5.37%
on 12/12/18
+1.12 (+9.39%)
since 11/21/18
52-Week
9.83 +32.76%
on 11/14/18
20.90 -37.56%
on 07/26/18
-2.98 (-18.59%)
since 02/22/18

Most Recent Stories

More News
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 13.02 (+2.20%)
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 13.02 (+2.20%)
Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

KTOV : 1.12 (-1.75%)
ATNX : 13.02 (+2.20%)
LLY : 124.13 (+1.15%)
ABBV : 80.03 (+1.63%)
Athenex Completes Enrollment Target for Breast Cancer Study

Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

ATNX : 13.02 (+2.20%)
PBYI : 26.91 (+2.99%)
RHHBY : 34.7000 (+0.42%)
PFE : 43.06 (+2.18%)
Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 13.02 (+2.20%)
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China

-- Chongqing Jingdong Pharmaceutical strengthens its product portfolio of innovative drugs with novel small molecule KX2-391

ATNX : 13.02 (+2.20%)
Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch...

ATNX : 13.02 (+2.20%)
Company News For Dec 13, 2018

Companies In The News Are: AEO,PVTL,LOW,ATNX

ATNX : 13.02 (+2.20%)
LOW : 105.93 (+0.39%)
AEO : 19.90 (+1.22%)
PVTL : 20.69 (-0.77%)
CORRECTION: Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer

In a press release issued under the same headline earlier today by Athenex, Inc., please note that the dosing regimen should be "mg/m," rather than "mg/kg," as was stated in the earlier release. The corrected...

ATNX : 13.02 (+2.20%)
Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that its global Phase 1b...

ATNX : 13.02 (+2.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ATNX with:

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

2nd Resistance Point 13.07
1st Resistance Point 12.91
Last Price 13.02
1st Support Level 12.47
2nd Support Level 12.19

See More

52-Week High 20.90
Fibonacci 61.8% 16.67
Fibonacci 50% 15.36
Fibonacci 38.2% 14.06
Last Price 13.02
52-Week Low 9.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar